Last Updated:

Q3 '20

Eiger BioPharmaceuticals

Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs. Eiger's lead clinical programs target Hepatitis Delta Virus (HDV) infection, the most serious form of human viral hepatitis. Eiger is developing two complementary treatments for HDV. Lonafarnib is a first-in-class, oral prenylation inhibitor in a global Phase 3 trial. Peginterferon lambda is a first-in-class, well-tolerated type III interferon entering Phase 3.



Burn Rate (Qtr)


Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Lonafarnib (Ritonavir)

Hepatitis Delta Virus

Phase 3


Peginterferon Lambda-1a (Lambda)


Phase 1


Recent Posts

See What The Community Is Saying - Click To See Full Post

EIGR - Eiger BioPharmaceutical...

Summary: Zokinvy increases survival by 2.5 years in children and young adults with Progeria Rare Pediatric Disease Priority Review Voucher issued to Eiger from FDA Eiger to host an investor call, Nove...

EIGR - Announces Results of In...

#EIGR "announced results of an investigator sponsored study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.  The primary endpoint was duration of viral shed...

EIGR - Eiger Announces Peginte...

Summary: Week 48 (24 Weeks Post-Treatment) Results Presented 23% of Patients BLOQ or Undetectable HDV RNA at Week 48 55% of Patients Improved in Histology Activity Index (HAI) at Week 48 #EIGR "today...

EIGR - Eiger BioPharmaceutica...

Summary: Lambda significantly accelerated viral decline Viral clearance highly correlated with baseline viral loads- All Lambda-treated patients were below the infectivity threshold by Day 7 #EIGR "...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon